Sputnik V vaccine 98% effective against Covid-19: Russian scientists

The assessment is based on data from 3.8 million people

Sputnik V vaccine 98% effective against Covid-19: Russian scientists
Reuters
2 min read Last Updated : Apr 20 2021 | 1:50 AM IST
Russian scientists have found the Sputnik V vaccine 97.6 per cent effective against Covid-19 in a “real-world” assessment based on data from 3.8 million people, Moscow's Gamaleya Institute and the Russian Direct Investment Fund said on Monday.
 
The new effectiveness rate is higher than the 91.6 per cent rate outlined in results from a large-scale trial of Sputnik V that was published in The Lancet medical journal earlier this year, and compares favourably with data on the effectiveness of other Covid vaccines.
 
The new data was based on 3.8 million Russians who received both a first shot and a booster shot as part of the national roll-out of Sputnik V.
 
“This data confirms that Sputnik V demonstrates one of the best protection rates against coronavirus among all vaccines,” said Kirill Dmitriev, head of the RDIF sovereign wealth fund which is backing the vaccine.  The incidence of infection was calculated from the 35th day from the first injection, the statement said, showing an incidence rate of 0.027 per cent. The incidence of infection among unvaccinated adults during a considerable period following the launch of mass vaccination in Russia was 1.1 per cent, it said, without specifying the date range used. The new data will be published in a peer-reviewed medical journal next month.
 
The data was collated from a database kept by the health ministry that registers vaccinated people, as well as a separate database of people who were infected with Covid-19 in the country.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineRussia

Next Story